Curriculum vitae

	Mgr. Jiří Vrba, Ph.D.
	Date of birth: December 1971 Birthplace: Šternberk, Czech Republic

Contact:
Department of Medical Chemistry and Biochemistry
Hněvotínská 3, 775 15 Olomouc, Czech Republic
Tel.: 420-585 632 310, Fax.: +420-585 632 302
E-mail: vrbambv@seznam.cz

Education

1990-1995		M.S. in Analytical Chemistry, Faculty of Science, Palacký University, Olomouc
2001-2005		Ph.D. in Biochemistry, Department of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacký University, Olomouc

Positions

1995-1996		Compulsory military service
1996-2001		Deputy department head and analyst, Analytical laboratory of Tekro Ltd., Prague
2004		Research Assistant, Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc

Postgraduate training

2004 FEBS Lecture Course on Cellular Signaling, Dubrovnik, Croatia
2005 Department of Drug Safety Evaluation, Sanofi Aventis, Vitry-Sur-Seine/Alfortville, France
2009 Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Major interests

Cellular signalling pathways
Biological activity of natural substances

PUBLICATIONS 10 articles
17 conference presentations

Citation index (SCI): 46

Recent publications:

1. Vrba J., Dvořák Z., Ulrichová J., Modrianský M. Conventional protein kinase C isoenzymes undergo dephosphorylation in neutrophil-like HL-60 cells treated by chelerythrine or sanguinarine. Cell Biol. Toxicol. 24(1), 39-53 (2008).

2. Vrba J., Doležel P., Vičar J., Modrianský M., Ulrichová J. Chelerythrine and dihydrochelerythrine induce G1 phase arrest and bimodal cell death in human leukemia HL-60 cells. Toxicol. In Vitro 22(4), 1008-1017 (2008).

3. Vrba J., Doležel P., Vičar J., Ulrichová J. Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. Toxicol. In Vitro 23(4), 580-588 2009).

4. Vrba J., Dolezel P., Ulrichova J. Neutrophilic differentiation modulates the apoptotic response of HL-60 cells to sodium butyrate and sodium valproate. Neoplasma 57(5), 438-448 (2010).